In our previously published work [9] we discuss the rationale behind utilising analogues of the FDA-approved drugs frentizole and riluzole as inhibitors of 17β-HSD10 for potential therapeutics in AD. This evidence concerns the gene HSD17B10 and Alzheimer disease.